HomeCompareHTBX vs EQR

HTBX vs EQR: Dividend Comparison 2026

HTBX yields 84.03% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HTBX wins by $1.94M in total portfolio value
10 years
HTBX
HTBX
● Live price
84.03%
Share price
$2.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.98M
Annual income
$593,470.68
Full HTBX calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — HTBX vs EQR

📍 HTBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHTBXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HTBX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HTBX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HTBX
Annual income on $10K today (after 15% tax)
$7,142.86/yr
After 10yr DRIP, annual income (after tax)
$504,450.08/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, HTBX beats the other by $501,203.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HTBX + EQR for your $10,000?

HTBX: 50%EQR: 50%
100% EQR50/50100% HTBX
Portfolio after 10yr
$1.01M
Annual income
$298,645.14/yr
Blended yield
29.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

HTBX
Analyst Ratings
8
Buy
Consensus: Buy
Altman Z
-22.5
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HTBX buys
0
EQR buys
0
No recent congressional trades found for HTBX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHTBXEQR
Forward yield84.03%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1.98M$40.5K
Annual income after 10y$593,470.68$3,819.61
Total dividends collected$1.73M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: HTBX vs EQR ($10,000, DRIP)

YearHTBX PortfolioHTBX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$19,103$8,403.36$11,248$547.57+$7.9KHTBX
2$35,444$15,003.03$12,701$666.53+$22.7KHTBX
3$63,940$26,014.99$14,405$814.59+$49.5KHTBX
4$112,276$43,860.35$16,413$999.84+$95.9KHTBX
5$192,114$71,978.72$18,795$1,232.92+$173.3KHTBX
6$320,666$115,104.62$21,639$1,527.95+$299.0KHTBX
7$522,671$179,557.63$25,057$1,903.80+$497.6KHTBX
8$832,781$273,523.56$29,197$2,385.87+$803.6KHTBX
9$1,298,375$407,299.36$34,250$3,008.70+$1.26MHTBX
10$1,982,732$593,470.68$40,467$3,819.61+$1.94MHTBX

HTBX vs EQR: Complete Analysis 2026

HTBXStock

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Full HTBX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this HTBX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HTBX vs SCHDHTBX vs JEPIHTBX vs OHTBX vs KOHTBX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.